| |
Monday, April 21, 2025 | 12pm ET / 9am PT Join us for an exclusive webinar exploring groundbreaking findings from the DUTRENEO trial, which evaluated the role of predictive biomarkers in guiding neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). Register today. 
|
|
Today’s Big NewsApr 9, 2025 |
|
Access this resource for key insights from industry leaders on the use of in-country liquid biopsy testing for global clinical trials. Country-specific regulations often prevent or delay access to testing results, decreasing population sizes and increasing timing and costs. Download now to see how to overcome these challenges. 
|
|
| By Gabrielle Masson In the latest of a string of clawbacks, the Department of Health and Human Services is now sharing plans to cut contract spending by 35% across all divisions. |
|
|
|
By Zoey Becker Reckitt Beckiser and Organon are laying off employees in New Jersey as both companies are undergoing separate restructurings. |
By Gabrielle Masson On Monday, a federal judge permanently blocked the National Institutes of Health from implementing indirect cost caps on research grants. The NIH is now appealing. |
By Kevin Dunleavy A New York City federal court has dismissed a proposed class action lawsuit against Bristol Myers Squibb that accused the drugmaker of deploying anticompetitive tactics to protect the market exclusivity of key multiple myeloma drug Pomalyst. |
|
Scaling advanced biotherapeutics is becoming more complex due to the rise of therapies like cell and gene treatments, RNA therapeutics and monoclonal antibody variants. Access this report to discover key strategies to optimize production, ensure compliance and accelerate commercialization. Download now. 
|
|
By Conor Hale Looking to get its earnings out early, PacBio posted preliminary revenue estimates this week ahead of its full quarterly report scheduled for May 8. |
By Darren Incorvaia The Trump administration’s effort to slash federal funding to universities has found its latest targets, with the government reportedly freezing $1 billion in funds to Cornell University and $790 million to Northwestern University. |
By Andrea Park As it advances a monoclonal antibody targeting Guillain-Barré syndrome, Annexon Biosciences is embarking on another effort to improve treatment of the rare condition. |
By James Waldron AstraZeneca has been busy in recent years picking up a shopping list of assets and companies that have pumped up its oncology pipeline. |
By Joseph Keenan DHL Group is earmarking 2 billion euros ($2.2 billion) to bulk up its healthcare supply chain operations in order to meet growing demand from the biopharma industry. |
By James Waldron With two attempts to merge with other companies having collapsed, Vincerx Pharma has been left with no choice but to start winding down. |
By Conor Hale Caris' MI Cancer Seek assay, greenlit by the FDA in November, examines 228 tumor genes to help find eligible patients for targeted treatments. |
By Nick Paul Taylor Merz Aesthetics has extended its starry marketing strategy, signing up Salma Hayek Pinault as the first global brand ambassador for its noninvasive skin-lifting device. |
By Kevin Dunleavy After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Senior Writer Paige Minemyer chats with Jason Oberfest, vice president of healthcare at Oura, to discuss how the company is approaching its push into healthcare. |
|
|---|
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Avoid costly mistakes and ensure your clinical development program meets the highest standards by reading WCG’s whitepaper on Imaging Core Labs, Endpoint Adjudication Committees (EAC), and other safety reviews. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
+(1)+(1).png)
